Early salvage radiotherapy following radical prostatectomy

David Pfister, Michel Bolla, Alberto Briganti, Peter Carroll, Cesare Cozzarini, Steven Joniau, Hein Van Poppel, Mack Roach, Andrew Stephenson, Thomas Wiegel, Michael J. Zelefsky

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Context Depending on the pathologic tumour stage, up to 60% of prostate cancer patients who undergo radical prostatectomy will develop biochemical relapse and require further local treatment. Objectives We reviewed the results of early salvage radiation therapy (RT), defined as prostate-specific antigen (PSA) values prior to RT <0.5 ng/ml in the setting of lymph node-negative disease. Evidence acquisition Ten retrospective studies, including one multicentre analysis, were used for this analysis. Among them, we received previously unpublished patient characteristics and updated outcome data from five retrospective single-centre trials to perform a subgroup analysis for early salvage RT. Evidence synthesis Patients treated with early salvage RT have a significantly improved biochemical recurrence-free survival (BRFS) rate compared with those receiving salvage RT initiated after PSA values are >0.5 ng/ml. Similarly, within the cohort of patients with pre-RT PSA values 0.5 ng/ml. Whether the routine application of early salvage RT in patients with initially undetectable PSA levels will be associated with demonstrable clinical benefit awaits the results of ongoing prospective trials.

Original languageEnglish
Pages (from-to)1034-1043
Number of pages10
JournalEuropean Urology
Volume65
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Prostatectomy
Radiotherapy
Prostate-Specific Antigen
Salvage Therapy
Secondary Prevention
Prostatic Neoplasms
Recurrence
Neoplasms
Therapeutics

Keywords

  • Biochemical recurrence-free survival
  • Early salvage radiotherapy
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Pfister, D., Bolla, M., Briganti, A., Carroll, P., Cozzarini, C., Joniau, S., ... Zelefsky, M. J. (2014). Early salvage radiotherapy following radical prostatectomy. European Urology, 65(6), 1034-1043. https://doi.org/10.1016/j.eururo.2013.08.013

Early salvage radiotherapy following radical prostatectomy. / Pfister, David; Bolla, Michel; Briganti, Alberto; Carroll, Peter; Cozzarini, Cesare; Joniau, Steven; Van Poppel, Hein; Roach, Mack; Stephenson, Andrew; Wiegel, Thomas; Zelefsky, Michael J.

In: European Urology, Vol. 65, No. 6, 2014, p. 1034-1043.

Research output: Contribution to journalArticle

Pfister, D, Bolla, M, Briganti, A, Carroll, P, Cozzarini, C, Joniau, S, Van Poppel, H, Roach, M, Stephenson, A, Wiegel, T & Zelefsky, MJ 2014, 'Early salvage radiotherapy following radical prostatectomy', European Urology, vol. 65, no. 6, pp. 1034-1043. https://doi.org/10.1016/j.eururo.2013.08.013
Pfister, David ; Bolla, Michel ; Briganti, Alberto ; Carroll, Peter ; Cozzarini, Cesare ; Joniau, Steven ; Van Poppel, Hein ; Roach, Mack ; Stephenson, Andrew ; Wiegel, Thomas ; Zelefsky, Michael J. / Early salvage radiotherapy following radical prostatectomy. In: European Urology. 2014 ; Vol. 65, No. 6. pp. 1034-1043.
@article{7d5c728240b646ce99bc2009c4735239,
title = "Early salvage radiotherapy following radical prostatectomy",
abstract = "Context Depending on the pathologic tumour stage, up to 60{\%} of prostate cancer patients who undergo radical prostatectomy will develop biochemical relapse and require further local treatment. Objectives We reviewed the results of early salvage radiation therapy (RT), defined as prostate-specific antigen (PSA) values prior to RT <0.5 ng/ml in the setting of lymph node-negative disease. Evidence acquisition Ten retrospective studies, including one multicentre analysis, were used for this analysis. Among them, we received previously unpublished patient characteristics and updated outcome data from five retrospective single-centre trials to perform a subgroup analysis for early salvage RT. Evidence synthesis Patients treated with early salvage RT have a significantly improved biochemical recurrence-free survival (BRFS) rate compared with those receiving salvage RT initiated after PSA values are >0.5 ng/ml. Similarly, within the cohort of patients with pre-RT PSA values 0.5 ng/ml. Whether the routine application of early salvage RT in patients with initially undetectable PSA levels will be associated with demonstrable clinical benefit awaits the results of ongoing prospective trials.",
keywords = "Biochemical recurrence-free survival, Early salvage radiotherapy, Prostate cancer, Radiotherapy",
author = "David Pfister and Michel Bolla and Alberto Briganti and Peter Carroll and Cesare Cozzarini and Steven Joniau and {Van Poppel}, Hein and Mack Roach and Andrew Stephenson and Thomas Wiegel and Zelefsky, {Michael J.}",
year = "2014",
doi = "10.1016/j.eururo.2013.08.013",
language = "English",
volume = "65",
pages = "1034--1043",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Early salvage radiotherapy following radical prostatectomy

AU - Pfister, David

AU - Bolla, Michel

AU - Briganti, Alberto

AU - Carroll, Peter

AU - Cozzarini, Cesare

AU - Joniau, Steven

AU - Van Poppel, Hein

AU - Roach, Mack

AU - Stephenson, Andrew

AU - Wiegel, Thomas

AU - Zelefsky, Michael J.

PY - 2014

Y1 - 2014

N2 - Context Depending on the pathologic tumour stage, up to 60% of prostate cancer patients who undergo radical prostatectomy will develop biochemical relapse and require further local treatment. Objectives We reviewed the results of early salvage radiation therapy (RT), defined as prostate-specific antigen (PSA) values prior to RT <0.5 ng/ml in the setting of lymph node-negative disease. Evidence acquisition Ten retrospective studies, including one multicentre analysis, were used for this analysis. Among them, we received previously unpublished patient characteristics and updated outcome data from five retrospective single-centre trials to perform a subgroup analysis for early salvage RT. Evidence synthesis Patients treated with early salvage RT have a significantly improved biochemical recurrence-free survival (BRFS) rate compared with those receiving salvage RT initiated after PSA values are >0.5 ng/ml. Similarly, within the cohort of patients with pre-RT PSA values 0.5 ng/ml. Whether the routine application of early salvage RT in patients with initially undetectable PSA levels will be associated with demonstrable clinical benefit awaits the results of ongoing prospective trials.

AB - Context Depending on the pathologic tumour stage, up to 60% of prostate cancer patients who undergo radical prostatectomy will develop biochemical relapse and require further local treatment. Objectives We reviewed the results of early salvage radiation therapy (RT), defined as prostate-specific antigen (PSA) values prior to RT <0.5 ng/ml in the setting of lymph node-negative disease. Evidence acquisition Ten retrospective studies, including one multicentre analysis, were used for this analysis. Among them, we received previously unpublished patient characteristics and updated outcome data from five retrospective single-centre trials to perform a subgroup analysis for early salvage RT. Evidence synthesis Patients treated with early salvage RT have a significantly improved biochemical recurrence-free survival (BRFS) rate compared with those receiving salvage RT initiated after PSA values are >0.5 ng/ml. Similarly, within the cohort of patients with pre-RT PSA values 0.5 ng/ml. Whether the routine application of early salvage RT in patients with initially undetectable PSA levels will be associated with demonstrable clinical benefit awaits the results of ongoing prospective trials.

KW - Biochemical recurrence-free survival

KW - Early salvage radiotherapy

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84899584952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899584952&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2013.08.013

DO - 10.1016/j.eururo.2013.08.013

M3 - Article

C2 - 23972524

AN - SCOPUS:84899584952

VL - 65

SP - 1034

EP - 1043

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -